Bristol-Myers Squibb Co. (BMY): Price and Financial Metrics

BMY POWR Grades

• Value is the dimension where BMY ranks best; there it ranks ahead of 97.68% of US stocks.
• The strongest trend for BMY is in Quality, which has been heading down over the past 179 days.
• BMY ranks lowest in Momentum; there it ranks in the 3rd percentile.

BMY Stock Summary

• With a market capitalization of $146,585,266,597, BRISTOL MYERS SQUIBB CO has a greater market value than 98.87% of US stocks.
• BRISTOL MYERS SQUIBB CO's stock had its IPO on January 1, 1986, making it an older stock than 93.28% of US equities in our set.
• Over the past twelve months, BMY has reported earnings growth of -284.97%, putting it ahead of merely 5.94% of US stocks in our set.
• Stocks that are quantitatively similar to BMY, based on their financial statements, market capitalization, and price volatility, are TXN, NVS, AMGN, SNY, and DE.
• Visit BMY's SEC page to see the company's official filings. To visit the company's web site, go to www.bms.com.

BMY Valuation Summary

• In comparison to the median Healthcare stock, BMY's price/sales ratio is 41.51% lower, now standing at 3.1.
• Over the past 243 months, BMY's price/sales ratio has gone up 0.4.

Below are key valuation metrics over time for BMY.

BMY Growth Metrics

Its 3 year net cashflow from operations growth rate is now at 163.12%.
• The year over year revenue growth rate now stands at 9.69%.
• Its 5 year price growth rate is now at 17.47%.

BMY's revenue has moved up $22,971,000,000 over the prior 33 months.

The table below shows BMY's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-06-30	47,144	15,396	6,617
2022-03-31	46,960	16,195	6,251
2021-12-31	46,385	16,207	6,994
2021-09-30	45,468	15,820	-5,405
2021-06-30	44,384	12,773	-5,079
2021-03-31	42,810	13,982	-6,219

BMY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BMY has a Quality Grade of B, ranking ahead of 79.64% of graded US stocks.
• BMY's asset turnover comes in at 0.38 -- ranking 124th of 680 Pharmaceutical Products stocks.
• PAHC, ACUR, and XLRN are the stocks whose asset turnover ratios are most correlated with BMY.

The table below shows BMY's key quality metrics over time.